{"id":2677,"date":"2021-09-29T10:08:15","date_gmt":"2021-09-29T10:08:15","guid":{"rendered":"https:\/\/aceoncology.org\/?p=2677"},"modified":"2021-10-25T07:27:21","modified_gmt":"2021-10-25T07:27:21","slug":"adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/","title":{"rendered":"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9"},"content":{"rendered":"\n<p>\u6bcf\u5e74\u7684ESMO\u76db\u4f1a\u90fd\u80fd\u628a\u5173\u5fc3\u80bf\u7624\u7684\u4eba\u4eec\u4e32\u8fde\u5728\u4e00\u8d77\u3002\u53d7\u75ab\u60c5\u5f71\u54cd\uff0c\u4eca\u5e74\u7684ESMO\u5e74\u4f1a\u4ecd\u5728\u7ebf\u4e0a\u4e3e\u529e\uff0c9\u670816\u65e5-21\u65e5\u671f\u95f4\uff0c\u6765\u81ea\u5168\u7403\u7684\u8d85\u8fc723\uff0c000\u540d\u53c2\u52a0\u4e86\u5927\u4f1a\uff0c\u4ee5\u4e86\u89e3\u591a\u5b66\u79d1\u80bf\u7624\u7ba1\u7406\u7684\u6700\u65b0\u8fdb\u5c55\u3001\u4e89\u8bae\u548c\u6311\u6218\u3002\u5f97\u76ca\u4e8eCOVID-19\u75ab\u82d7\u63a5\u79cd\u548c\u6838\u9178\u68c0\u6d4b\uff0c\u4eca\u5e74\u4f1a\u8bae\u7684\u90e8\u5206\u56fd\u9645\u8bb2\u8005\u548c\u8ba8\u8bba\u5609\u5bbe\u80fd\u591f\u4eb2\u4e34\u5df4\u9ece\u73b0\u573a\u6f14\u8bb2\uff0c\u8fdb\u4e00\u6b65\u52a0\u5f3a\u5bf9\u65b0\u8fdb\u5c55\u548c\u5b9e\u8df5\u66f4\u65b0\u6570\u636e\u7684\u8ba8\u8bba\u3002\u5927\u4f1a\u516c\u5e03\u4e86\u603b\u5171\u8fd12000\u7bc7\u6458\u8981\u548c68\u7bc7\u6700\u65b0\u7a81\u7834\u6027\u8fdb\u5c55\u6458\u8981\uff08LBA\uff09\u3002\u5728\u7b2c\u4e00\u6b21\u4e3b\u5e2d\u7814\u8ba8\u4f1a\u671f\u95f4\uff0c\u6765\u81ea\u897f\u73ed\u7259\u5df4\u585e\u7f57\u90a3\u56fd\u9645\u4e73\u817a\u764c\u4e2d\u5fc3\uff08IBCC\uff09\u53caVall d\u2019Hebron\u80bf\u7624\u7814\u7a76\u6240\u7684Javier Cort\u00e9s\u535a\u58eb\uff0c\u6c47\u62a5\u4e86\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u3001\u5f00\u653e\u6807\u7b7e\u30013\u671f<a href=\"https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.esmo\/static\/esmo2021_abstractsv2\/LBA1.html.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">DESTINY-Breast03<\/a>\u7814\u7a76\u7684\u7ed3\u679c\uff0c\u8fd9\u4e00\u7ed3\u679c\u4e07\u4f17\u77a9\u76ee\u3002\u8fd9\u662f\u7b2c\u4e00\u9879\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u7d2b\u6749\u70f7\u7c7b\u5316\u7597\u7684HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\uff08mBC\uff09\u60a3\u8005\u4e2d\u6bd4\u8f83\u4e24\u79cdHER2\u9776\u5411\u6297\u4f53-\u836f\u7269\u5076\u8054\uff08ADC\uff09trastuzumab deruxtecan\uff08T-DXd\uff09\u548ctrastuzumab emtansine\uff08T-DM1\uff09\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u7684\u7814\u7a76\u3002\u57fa\u4e8e<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1914510\" target=\"_blank\" rel=\"noreferrer noopener\">DESTINY-Breast01\u7814\u7a76<\/a>\u7ed3\u679c\uff0cT-DXd\u83b7\u6279\u7528\u4e8e\u65e2\u5f80\u63a5\u53d7\u8fc7\u91cd\u5ea6\u6cbb\u7597\u7684HER2\u9633\u6027mBC\u60a3\u8005\uff08\u63a5\u53d7\u8fc7\u22652\u79cd\u6297HER2\u6cbb\u7597\u65b9\u6848\u540e\uff09\u3002<\/p>\n\n\n\n<p>\u5728DESTINY-03\u4e2d\uff0c524\u4f8b\u65e2\u5f80\u63a5\u53d7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u7d2b\u6749\u70f7\u6cbb\u7597\u7684HER2\u9633\u6027mBC\u60a3\u8005\u968f\u673a\u63a5\u53d7T-DXd\u6216T-DM1\u6cbb\u7597\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u76f2\u6001\u72ec\u7acb\u4e2d\u5fc3\u5ba1\u67e5\uff08BICR\uff09\u8bc4\u4f30\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u3002T-DXd\u7ec4\u672a\u8fbe\u5230\u4e2d\u4f4dPFS\uff0cT-DM1\u7ec4\u7684\u4e2d\u4f4dPFS\u4e3a6.8\u4e2a\u6708\uff08HR\uff0c0.28\uff1bP = 7.8 x 10<sup>-22<\/sup>\uff09\u3002\u6839\u636e\u7814\u7a76\u8005\u8bc4\u4f30\uff0cT-DXd\u7ec4\u7684mPFS\u662fT-DM1\u7ec4\u76843\u500d\u4ee5\u4e0a\uff0825.1\u4e2a\u6708vs.7.2\u4e2a\u6708\uff1bHR\uff0c0.26\uff1bP = 6.5 x 10<sup>-24<\/sup>\uff09\u3002\u4e9a\u7ec4\u5206\u6790\u4e2d\uff0c\u65e0\u8bba\u6fc0\u7d20\u53d7\u4f53\u72b6\u6001\u3001\u65e2\u5f80\u5e15\u59a5\u73e0\u5355\u6297\u6cbb\u7597\u3001\u57fa\u7ebf\u5185\u810f\u75be\u75c5\u3001\u662f\u5426\u5b58\u5728\u8111\u8f6c\u79fb\u548c\u65e2\u5f80\u6cbb\u7597\u7ebf\u6570\uff0c\u7ed3\u679c\u5747\u652f\u6301T-DXd\u3002\u5c3d\u7ba1\u5728\u8be5\u4e2d\u671f\u5206\u6790\u65f6\u4ec5\u968f\u8bbf\u4e8616\u4e2a\u6708\uff0c\u4f46\u603b\u751f\u5b58\uff08OS\uff09\u83b7\u76ca\u5448\u73b0\u4ee4\u4eba\u9f13\u821e\u7684\u8d8b\u52bf\u3002T-DXd\u7ec412\u4e2a\u6708OS\u7387\u4f30\u8ba1\u503c\u4e3a94.1%\uff0cT-DM1\u7ec4\u4e3a85.9%\uff08HR\uff0c0.56\uff1bP = 0.007172\uff09\u3002\u7136\u800c\uff0c\u8fd9\u5c1a\u672a\u8fbe\u5230\u9884\u5148\u5b9a\u4e49\u7684\u7edf\u8ba1\u5b66\u663e\u8457\u6027\u4e34\u754c\u503c\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cT-DXd\u7ec4\uff0879.7%\uff09\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u662fT-DM1\u7ec4\uff0834.2%\uff09\u7684\u4e24\u500d\u591a\u3002\u6b64\u5916\uff0cT-DXd\u7ec416%\u7684\u60a3\u8005\u8fbe\u5230\u5b8c\u5168\u7f13\u89e3\uff0c\u800cT-DM1\u7ec4\u4e3a8.7%\u3002T-DXd\u7684\u4e2d\u4f4d\u6cbb\u7597\u6301\u7eed\u65f6\u95f4\u4e5f\u662f2\u500d\u4ee5\u4e0a\uff0814.3\u4e2a\u6708vs 6.9\u4e2a\u6708\uff09\u3002\u91cd\u8981\u7684\u662f\uff0cT-Dxd\u7684\u5b89\u5168\u6027\u53ef\u63a7\uff0c\u4e14\u4e0eT-DM1\u5b89\u5168\u6027\u76f8\u5f53\u3002\u5927\u591a\u6570\u836f\u7269\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TEAE\uff09\u4e3a\u80c3\u80a0\u9053\u6216\u8840\u6db2\u5b66\u4e8b\u4ef6\u3002T-DXd\u7ec4\u6cbb\u7597\u4e2d\u6b62\u76f8\u5173\u7684\u6700\u5e38\u89c1TEAE\u4e3a\u95f4\u8d28\u6027\u80ba\u75be\u75c5\uff08ILD\uff09\/\u975e\u611f\u67d3\u6027\u80ba\u708e\uff088.2%\uff09\uff0cT-DM1\u7ec4\u4e3a\u8840\u5c0f\u677f\u51cf\u5c11\u75c7\uff082.7%\uff09\u3002\u5c3d\u7ba1T-DXd\u7ec4\u7684ILD\/\u975e\u611f\u67d3\u6027\u80ba\u708e\u53d1\u751f\u7387\u8f83\u9ad8\uff0810.5% vs. 1.9%\uff09\uff0c\u4f46\u4e0eDESTINY-Breast 01\u4e0d\u540c\uff0c3\u7ea7\u4e8b\u4ef6\u7684\u53d1\u751f\u7387\u4f4e\u4e8e1%\uff0c\u65e0\u60a3\u8005\u6b7b\u4ea1\u3002<\/p>\n\n\n\n<p>\u57fa\u4e8e\u5353\u8d8a\u7684\u7597\u6548\u548c\u53ef\u7ba1\u7406\u7684\u6bd2\u6027\uff0cDr Cort\u00e9s\u5f97\u51fa\u7ed3\u8bba\uff0cT-DXd\u5e94\u6210\u4e3a\u4e8c\u7ebfHER2\u9633\u6027 mBC\u7684\u65b0\u6807\u51c6\u6cbb\u7597\u3002\u6458\u8981\u7684\u8ba8\u8bba\u5609\u5bbe\u2014\u2014\u7ebd\u7ea6MSKCC\u7684Shanu Modi\u535a\u58eb\u540c\u610f\u5e76\u5f3a\u8c03T-DXd\u5728mBC\u4e2d\u7684\u7597\u6548\u662f\u524d\u6240\u672a\u6709\u7684\u3002\u91cd\u8981\u7684\u662f\uff0c\u80ba\u6bd2\u6027\u7684\u98ce\u9669\u4f4e\u4e8eDESTINY-Breast01\u7814\u7a76\uff0c\u8fd9\u53ef\u80fd\u662f\u7531\u4e8e\u5176\u5728\u66f4\u65e9\u6cbb\u7597\u7ebf\u4e2d\u4f7f\u7528\uff0c\u5e76\u4e14\u901a\u8fc7\u4ed4\u7ec6\u8b66\u60d5\u548c\u65e9\u671f\u5e72\u9884\u53ef\u66f4\u597d\u5730\u610f\u8bc6\u5230\u80ba\u6bd2\u6027\u3002\u5979\u5f3a\u8c03\uff0c\u5c3d\u7ba1\u672c\u7814\u7a76\u540e\u4ecd\u5b58\u5728\u5c1a\u672a\u56de\u7b54\u7684\u95ee\u9898\uff0c\u5373\u4f7f\u7528T-DXd\u4f5c\u4e3a\u4e8c\u7ebf\u6cbb\u7597\u5982\u4f55\u5f71\u54cd\u5305\u62ecT-DM1\u5728\u5185\u7684\u540e\u7eed\u6cbb\u7597\u7684\u7597\u6548\uff0c\u4f46\u8fd9\u4e0d\u59a8\u788d\u533b\u751f\u4f7f\u7528T-DXd\u4f5c\u4e3amBC\u7684\u4e8c\u7ebf\u6cbb\u7597\u3002<\/p>\n\n\n\n<p><strong>\u53c2\u8003\u6587\u732e<\/strong>:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br>Cort\u00e9s J, et al. <em>ESMO <\/em>2021; Abstract LBA1.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u6bcf\u5e74\u7684ESMO\u76db\u4f1a\u90fd\u80fd\u628a\u5173\u5fc3\u80bf\u7624\u7684\u4eba\u4eec\u4e32\u8fde\u5728\u4e00\u8d77\u3002\u53d7\u75ab\u60c5\u5f71\u54cd\uff0c\u4eca\u5e74\u7684ESMO\u5e74\u4f1a\u4ecd\u5728\u7ebf\u4e0a\u4e3e\u529e\uff0c9\u670816\u65e5-21 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2666,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[41,78],"tags":[],"class_list":["post-2677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-41","category-78"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9 - ACE Oncology<\/title>\n<meta name=\"description\" content=\"HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u63a5\u53d7trastuzumab deruxtecan\u4e8c\u7ebf\u6cbb\u7597\u540ePFS\u83b7\u76ca\u663e\u8457\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9 - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u63a5\u53d7trastuzumab deruxtecan\u4e8c\u7ebf\u6cbb\u7597\u540ePFS\u83b7\u76ca\u663e\u8457\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-29T10:08:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-25T07:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"657\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ACE Demo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ACE Demo\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\"},\"author\":{\"name\":\"ACE Demo\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\"},\"headline\":\"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9\",\"datePublished\":\"2021-09-29T10:08:15+00:00\",\"dateModified\":\"2021-10-25T07:27:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\"},\"wordCount\":104,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg\",\"articleSection\":[\"\u4f1a\u8bae\u52a8\u6001\",\"\u4f1a\u8bae\u901f\u9012\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\",\"name\":\"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9 - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg\",\"datePublished\":\"2021-09-29T10:08:15+00:00\",\"dateModified\":\"2021-10-25T07:27:21+00:00\",\"description\":\"HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u63a5\u53d7trastuzumab deruxtecan\u4e8c\u7ebf\u6cbb\u7597\u540ePFS\u83b7\u76ca\u663e\u8457\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg\",\"width\":1000,\"height\":657},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\",\"name\":\"ACE Demo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"caption\":\"ACE Demo\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9 - ACE Oncology","description":"HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u63a5\u53d7trastuzumab deruxtecan\u4e8c\u7ebf\u6cbb\u7597\u540ePFS\u83b7\u76ca\u663e\u8457","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/","og_locale":"zh_CN","og_type":"article","og_title":"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9 - ACE Oncology","og_description":"HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u63a5\u53d7trastuzumab deruxtecan\u4e8c\u7ebf\u6cbb\u7597\u540ePFS\u83b7\u76ca\u663e\u8457","og_url":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/","og_site_name":"ACE Oncology","article_published_time":"2021-09-29T10:08:15+00:00","article_modified_time":"2021-10-25T07:27:21+00:00","og_image":[{"width":1000,"height":657,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg","type":"image\/jpeg"}],"author":"ACE Demo","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"ACE Demo","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/"},"author":{"name":"ACE Demo","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0"},"headline":"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9","datePublished":"2021-09-29T10:08:15+00:00","dateModified":"2021-10-25T07:27:21+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/"},"wordCount":104,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg","articleSection":["\u4f1a\u8bae\u52a8\u6001","\u4f1a\u8bae\u901f\u9012"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/","url":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/","name":"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9 - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg","datePublished":"2021-09-29T10:08:15+00:00","dateModified":"2021-10-25T07:27:21+00:00","description":"HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u63a5\u53d7trastuzumab deruxtecan\u4e8c\u7ebf\u6cbb\u7597\u540ePFS\u83b7\u76ca\u663e\u8457","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/09\/Picture-Blog-Post-60_Destiny03-Trial.jpg","width":1000,"height":657},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/adc-trastuzumab-deruxtecan-new-second-line-option-for-her2-positive-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"Trastuzumab Deruxtecan\u4e3aHER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e8c\u7ebf\u6cbb\u7597\u65b0\u9009\u62e9"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0","name":"ACE Demo","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","caption":"ACE Demo"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=2677"}],"version-history":[{"count":8,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2677\/revisions"}],"predecessor-version":[{"id":2834,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2677\/revisions\/2834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/2666"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=2677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=2677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=2677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}